Dokter Blog: from the desk of Rahajeng Tunjungputri

Medicine et cetera by @ajengmd

Visiting Professor Lecture Series with Prof. J. Galama, MD, PhD: CMV Infection in Post-Transplant Patients

This article was previously published in the website of Faculty of Medicine Diponegoro University

Visiting Professor Lecture Series

Prof. J. Galama, MD, PhD: CMV Infection in Post-Transplant Patients

Prof. Jochem M.D. Galama, MD, PhD, a distinguished clinical virologist from the Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, delivered a special guest lecture, “CMV Infection in Post-Transplant Patients”, on Monday, 15 November 2010 in the Faculty of Medicine Diponegoro University (FMDU).

Prof. Jochem M.D. Galama, MD, PhD in FMDU. -image courtesy of aryardiant

Transplant patients are prone to infection, especially because they receive immunosuppressive therapy which consequently alters the normal immune response of the body. Different kinds of solid-organ transplants and human hematologic stem cell therapy pose different risks of infection to patients most likely due to the kinds of immunosuppressive therapy given.  Different viruses, including adenovirus, herpesviruses, parvovirus B19, polyoma virus (BK and JC), respiratory viruses (Influenza, RSV, rhinovirus) may be the etiological agent of post-transplant infection.

Cytomegalovirus, or CMV, is associated with poor outcome in hematologic stem cell transplant patients. CMV, is a Beta-herpes virus, possessing DNA genome of 235 kBp. CMV may be latent in myeloid precursor cells and posses strong immunomodulatory potential. In an immunocompetent host, CMV may cause primary or recurrent infection, with transmission through breastmilk from mother, saliva, urine, blood, sexual contact and transplant organ. The seroprevalence of CMV in the total population in the Netherlands is between 42% and 73%, while in Indonesia it may reach up to 90%. CMV disease is a combined clinical and virological diagnosis; and patients’ risk factors are very important in considering CMV disease.

Determining the CMV serostatus of donors and recipients before transplant procedure is mandatory. And pre-emptive and or prophylactic treatment for CMV is required when CMV disease is considered.

Prof. J. Galama current research focus is the role of enterovirus in type 1 diabetes. The lecture is part of the visiting professor lecture series held by Faculty of Medicine Diponegoro University in cooperation with Radboud University Nijmegen. This program was instituted to bring prominent international scholars and researchers to exchange their knowledge and experience, as well as have intensive discussions with the medical students, residents, fellows, and faculty of FMDU during the academic year. (dr. Rahajeng N. Tunjungputri -contributor)


Filed under: Uncategorized

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

png twitter

Follow my Twitter @ajengmd


Medicine is a growing field, and information presented here is reflective of the time of posting. Please refer to your physician for direct medical consultation. My views do not reflect those of my employers. --
Regards, Rahajeng

%d bloggers like this: